- Home
- SOPH vs TCRX Comparison
SOPH vs TCRX Comparison
Compare SOPH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 49.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOPH | TCRX |
|---|---|---|
| Price | $8.24 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.50 | $7.00 |
| AVG Volume (30 Days) | 642.5K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.37 | $0.29 |
| 52 Week High | $8.98 | $2.57 |
Technical Indicators
Market Signals| Indicator | SOPH | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 24.70 |
| Support Level | $4.63 | N/A |
| Resistance Level | $8.98 | $0.82 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 57.26 | 7.98 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.